The resolution recommends
• Establish a global framework for supporting essential medical R&D based upon the principle of an equitable contribution that all nations can make to financial investments in R&D. This includes the promotion of incentives to invest in useful R&D that meet patients’ needs and public health interest.
• Make global health and medicines a strategic sector. Governments must take action to ensure that R&D efforts address real needs, especially for people living in resource-poor settings, by harnessing new and innovative R&D collaborations with disease-endemic countries, and enabling progress in basic science and biomedicine to be translated into better, safer, and affordable health products drugs, vaccines, and diagnostics. These new essential medicines must be rapidly delivered to people, with special attention to those living in poverty.
• Create a new global system of finance for R&D of diseases that most affect the poor, such as malaria and other neglected diseases, as well as for important projects such as new treatments, diagnostics, and preventive tools for AIDS. Most of the 3.1 million persons who died of AIDS-related illnesses in 2005 were living in poverty. The development of health tools is a global public good, and requires a multilateral strategy for widespread success.
• Set up a Working Group of Member-States within WHO,
whose task is to deliver a final report with concrete proposals
to the Executive Board in January 2008.
Published by Drugs for Neglected Diseases Initiative - 1 Place St Gervais 1201 Geneva Switzerland
Editor: Jaya Banerji - Tel: +41 22 906 9230 - Fax: +41 22 906 9231 - www.dndi.org